Eye care company Alcon Inc. (ACL) said Friday that it has terminated the development of anecortave acetate to treat vision loss related to macular degeneration following an interim analysis of two studies that found the drug showing no effect on the primary or secondary endpoints.
The development program was designed to evaluate anecortave acetate for the treatment on the risk for developing sight-threatening choroidal neovascularization secondary to age-related macular degeneration.
The company also terminated two smaller studies with an identical design that were being conducted in Asia.
Alcon said it continues to study anecortave acetate administered as an anterior juxtascleral depot to reduce intraocular pressure in patients with open-angle glaucoma.
ACL closed Friday's regular trading session at $166.55, down 22 cents. In the after-hours, the shares further lost 86 cents.
For comments and feedback: editorial@rttnews.com